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Background: Interim positron emission tomography after 2 cycles of ABVD (iPET-2) is a good predictor of outcome
in advanced-stage classic Hodgkin lymphoma. So far, there are no other prognostic biomarkers capable of
identifying chemotherapy refractory patients with comparable accuracy. Despite the considerable amount of
evidence suggesting that antitumor immune surveillance is downregulated in classic Hodgkin lymphoma
(cHL), few data exist on the impairment of natural killer cell function and the role of their killer immunoglobulin-like
receptors (KIRs).
Methods: We investigated KIR gene frequencies, KIR haplotypes, and KIR-ligand combinations in a cohort of 135
patients with advanced-stage classic Hodgkin lymphoma and 221 healthy controls. We furthermore evaluated the
correlation of KIR genes and KIR haplotypes with the achievement of negative iPET-2.
Results: In the cohort of patients, the 5-year overall survival and progression-free survival were 93.6 and 79 %,
respectively. Homozygosity for KIR A haplotype and the HLA-C1 KIR ligand (KIR-AA/C1C1) was significantly higher
in healthy controls (15.7 vs. 4.8 %, p = 0.001). The KIR-AA genotype resulted to have a significant predictive power
for achieving iPET-2 negativity (p = 0.039).
Conclusions: Homozygosity for KIR A haplotype offers protection against classic Hodgkin lymphoma. The association
found for the KIR-AA genotype and achievement of negative iPET-2 suggests that KIR-AA could be used in clinical
practice to enhance the chemosensitivity predictive power of iPET-2. Our results point to the possibility of
adapting treatment strategies based on the combination of KIR biomarkers and PET scan.
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Cure rates in classic Hodgkin lymphoma (cHL) range
from 70 to 90 %, but complete recovery of patients is
burdened by long-term toxicities of chemoradiation
treatment, particularly heart and lung injury and sec-
ondary neoplasms [1]. Although in recent years interim
[18F]-fluoro-2-deoxy-D-glucose positron emission tom-
ography carried out after 2 cycles of doxorubicin, bleo-
mycin, vinblastine, dacarbazine (ABVD) treatment
(iPET-2) has emerged as a powerful predictor of treat-
ment outcome in advanced-stage cHL patients [2], no
other biomarkers have been shown capable of predicting
treatment outcome at baseline with the same accuracy.
Because of its unique histology, cHL is an interesting
study model for the identification of new immunological
and immunogenetic factors that may confer susceptibility
to tumor or influence response to treatment [3]. In fact,
the peculiar architecture of “malignant lymphogranuloma”
is characterized by the presence of only a few neoplastic
cells—Hodgkin-Reed-Sternberg (HRS) cells—growing
in a microenvironment rich with immune system cells
that are incapable of mounting an effective antitumor
response [4].
Despite the considerable amount of evidence suggest-
ing that antitumor immune surveillance is downregu-
lated in cHL [5], few data exist on the impairment of
natural killer (NK) cell function in cHL. NK cells are a
key component of the innate immune system and play
an important role in antitumor surveillance. Their activ-
ity is regulated by several receptor families, including
killer cell immunoglobulin-like receptors (KIRs) which
recognize human leukocyte antigen (HLA) class I mole-
cules expressed on target cells [6]. NK cells express differ-
ent combinations of the KIR2DL1, KIR2DL2, KIR2DL3,
KIR2DL4, KIR2DL5, KIR3DL1, KIR3DL2, and KIR3DL3
inhibitory KIR genes and KIR2DS1, KIR2DS2, KIR2DS3,
KIR2DS4, KIR2DS5, and KIR3DS1 activating KIR genes
[7]. The KIR gene family has been divided into two broad
groups of haplotypes according to gene content. KIR A
haplotypes encode the KIR2DL3, KIR2DL1, KIR3DL1, and
KIR3DL2 inhibitory genes and the KIR2DS4 activating
gene. These haplotypes have identical KIR gene content,
but can differ for allelic polymorphism. KIR B haplo-
types contain various combinations of both activating
and inhibitory KIR genes and show less allelic poly-
morphism [8, 9].
KIR receptors recognize four mutually exclusive epi-
topes carried by HLA-A, HLA-B, and HLA-C class I mol-
ecules: C1, C2, Bw4, and A3/A11. HLA-C is known to
consist of two functional classes of allotypes, depending
on an amino acid dimorphism at residue 80 of the α1-
helix. The C1 epitope is carried by HLA-C allotypes with
asparagine at position 80 and by some HLA-B alleles in
the Asian population that have asparagine at position 80and valine at position 76. The C2 epitope is carried by
HLA-C allotypes characterized by a lysine at position 80
of the α1-helix. The Bw4 epitope is carried by HLA-A and
HLA-B allotypes that have arginine at position 83. The
A3/11 epitope of HLA-A is carried by two HLA-A allo-
types, HLA-A*03 and HLA-A*11 [10, 11].
The diversity in gene content of KIR haplotypes and
the extensive polymorphism of HLA and KIR genes
make it possible for an individual to express KIR genes
for which there are no HLA ligands and vice versa,
which thus determines extremely variable immunoge-
netic profiles among individuals [12]. KIR A haplotypes
seem to provide better immune surveillance against viral
infections and tumor cells, whereas KIR B haplotypes
seem to have a favorable role during pregnancy [10].
Although there is a growing interest in the role of NK
cells in oncohematologic disorders [13–17], to the best of
our knowledge, there is only one previous report investi-
gating the possible involvement of KIR genes in cHL [18].
To gain further insight into the role of NK cells in cHL
and their possible impact on response to treatment, we in-
vestigated KIR gene frequencies, KIR haplotypes, and
KIR-ligand combinations in a cohort of advanced-stage
cHL patients compared to healthy controls. Moreover, we
evaluated the correlation of KIR genes and KIR haplotypes
with the achievement of negative iPET-2 and their pos-
sible impact on progression-free survival (PFS).Methods
Ethics, consent, and permissions
In accordance with the 1975 guidelines of the Declaration
of Helsinki and after obtaining approval for the study from
the four competent local Ethics Committees (Cagliari,
Catania, Cuneo, and Reggio Calabria), the medical staff of
each participating center exhaustively informed their pa-
tients of the potential risks and benefits of the planned
treatment and the need for periodical clinical and labora-
tory checkups.
Patients, healthy controls, and treatment protocols
One hundred and thirty-five patients with advanced-
stage cHL were included in the study. All patients were
enrolled in the international prospective multicenter
clinical trial HD 0607 (NCT00795613). A complete data
set containing all the following parameters was collected
at baseline: age, sex, histological subtype, presence of B-
symptoms (fever, weight loss exceeding 10 % of body
weight in 6 months, night sweats), extranodal involve-
ment or bulky mass, absolute lymphocyte and neutrophil
count, hemoglobin and albumin, Ann Arbor stage, and
International Prognostic Score (IPS) [19].
All the patients received two courses of standard
ABVD treatment before undergoing iPET-2 to assess
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groups according to the results of iPET-2. Patients with
positive iPET-2 were randomly assigned to receive four
courses of escalated BEACOPP (rituximab, bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, prednisone) or R-BEACOPP (BEACOPP
supplemented with rituximab), followed by four courses
of baseline BEACOPP or R-BEACOPP. Patients with a
negative iPET-2 scan continued with four more courses
of ABVD. Patients in complete remission with a negative
final PET scan who presented bulky disease at baseline
or showed a PET-negative residual mass at the end of
chemotherapy were randomly assigned to receive con-
solidation radiotherapy or no further treatment.
A group of 221 healthy subjects (104 males and 117
females) with a mean age of 35 (range 25–55 years) were
selected for control purposes.
HLA and KIR typing
HLA typing was performed in healthy controls and patients
using commercially available PCR kits with sequence-
specific primers (HLA-A-B-C SSP Combi Tray, Olerup,
Stockholm, Sweden, and Micro SSP™ Generic HLA class I
typing tray SSP1L, One Lambda, Inc., Canoga Park, CA,
USA). HLA-C groups C1 and C2 and HLA-Bw4 were de-
termined by high-resolution typing for the alleles at the
HLA-A, HLA-B, and HLA-C loci using a polymerase chain
reaction-sequence-specific primer (PCR-SSP) method ac-
cording to the manufacturers’ instructions (allele-specific
PCR-SSP kits: Olerup SSP AB, Stockholm, Sweden).
Distribution of KIR genes (KIR2DL1, KIR2DL2, KIR2DL3,
KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR
2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3,
KIR3DS1) were determined by PCR-SSP using a previously
reported method [20, 21].
Patients were stratified into two groups according to
homozygosity for KIR A haplotype (KIR genotype AA)
and heterozygosity or homozygosity for KIR B haplotype
(KIR genotypes AB and BB, referred together as KIR
genotype Bx) [21, 22].
Statistical analysis
KIR gene frequencies, KIR haplotypes, and KIR-ligand
combinations were compared between cHL patients and
healthy controls as well as between cHL patients who
achieved negative iPET-2 and those who did not. The
abovementioned set of independent variables was in-
cluded in univariate and multivariate analyses. Where
appropriate, significant differences were calculated using
Fisher’s two-sided exact test or Pearson’s chi-squared test.
Variables with a p value lower than 0.2 in univariate
analysis were included in multivariate analysis using a
multi-step forward binary logistic regression model, where
negative iPET-2 scan was considered a dependent variable.Only p values ≤0.05 were considered to be statistically sig-
nificant. The probability of achieving overall survival (OS)
and PFS was calculated using the Kaplan-Meier method.
Comparisons were also made to assess PFS in patient sub-
groups according to KIR haplotype or iPET results. The
log-rank test was used to compare the groups of patients.Results
Characteristics of patients and controls
The demographic and clinical characteristics of 135
advanced-stage cHL patients (67 males and 68 females,
mean follow-up 35 months, range 8–60) and 221 con-
trols are shown in Table 1. The overall mean age at
diagnosis was 34 years (range 15–69). The large major-
ity of patients (80 %) had a nodular sclerosing histo-
logical subtype. Bulky mass and “B” symptoms were
found in 40.7 and 54.1 %, respectively. According to the
HD 0607 inclusion criteria, all patients belonged to ad-
vanced Ann Arbor stages (IIb–IV) with an unfavorable
IPS in 28.9 % of cases. The demographic characteristics
of the 221 healthy controls (104 males and 117 females)
with a mean age of 35 (range 25–55 years) were not
statistically different from the cHL cohort.KIR gene frequencies, KIR haplotypes, and KIR-HLA ligand
combinations in cHL patients and controls
Table 2 shows KIR gene frequencies, KIR haplotypes, and
KIR-HLA ligand combinations in 135 cHL patients and
221 healthy controls. No significant differences were found
between patients and controls for the frequencies of the
single activating and inhibitory KIR genes. Overall, the
healthy controls had significantly higher frequencies of the
HLA-C1 ligand (C1/C1 or C1/C2) compared to patients
(72.7 vs. 60 %, p = 0.014); on the other hand, frequency of
the HLA-C2 ligand (C2/C2 or C1/C2) was significantly
higher in cHL patients (88.9 vs. 76 %, p = 0.003). No sig-
nificant differences were found for frequencies of the
HLA-Bw4 ligand within the two groups. Homozygosity for
KIR A haplotype combined with homozygosity for the
HLA-C1 ligand (KIRAA/C1C1) was significantly higher in
healthy controls (15.7 vs. 4.8 %, p = 0.001). The analysis of
the combinations of KIR genes and their specific ligands
showed a significantly higher frequency of KIR3DS1 and
KIR3DL1 when combined with the absence of their spe-
cific ligand HLA-Bw4 in cHL patients (15.5 vs. 6.3 %, p =
0.006 and 33.3 vs. 21.3 %, p = 0.013, respectively).KIR gene frequencies, KIR haplotypes, and KIR-HLA ligand
combinations in cHL patients with positive or negative
iPET-2 results
Table 3 shows HLA and KIR gene frequencies, KIR hap-
lotypes, and the combinations between KIRs and their
Table 1 Characteristics of 135 patients with advanced-stage classic Hodgkin lymphoma and 221 healthy controls
Patients n = 135 Controls n = 221 p value
Sex, no. (%)
Male 67 (49.6) 104 (47.1) NS
Female 68 (50.4) 117 (52.9) NS
Age at diagnosis, mean (range) 34 (15–69) 35 (25–55) NS
Disease subtype, no. (%)




Albumin, g/dl, mean (range) 3.8 (2.2–5.1)
Hemoglobin, g/dl, mean (range) 13.0 (8.3–14.2)
Lymphocytes, ×103/μL, mean (range) 1.75 (0.3–4.9)
Neutrophils, ×103/μL, mean (range) 8.55 (2.1–35.8)
Bulky mass, no. (%) 55 (40.7)
“B” symptoms, no. (%) 73 (54.1)
Extranodal extension, no. (%) 42 (31.1)
IPS score ≥ 4 (unfavorable in advanced stages) 39 (28.9)
Ann Arbor stage 1–2a, no. (%) 0 (0)
Stage 2b, no. (%) 57 (42.2)
Stage 3, no. (%) 45 (33.3)
Stage 4, no. (%) 33 (24.5)
NS not significant
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comparison with 102 patients with negative iPET-2.
A significantly higher frequency of the KIR2DS2 acti-
vating KIR gene was found in patients with positive
iPET-2 (81.8 vs. 50 %, p = 0.001). Homozygosity for
KIR A haplotype was present with a significantly higher
frequency in patients with negative iPET-2 (36.3 vs.
15.2 %; p = 0.03). In particular, only 5 of the 33 patients
with positive iPET-2 had KIR genotype AA, whereas
the remaining 28 (84.8 %) had KIR genotype Bx.
Homozygosity for KIR A haplotype remained the only
predictive factor for the achievement of negative iPET-
2 (p = 0.039). The analysis of HLA-KIR combinations
showed that cHL patients with a positive iPET-2 scan
had higher frequencies of the activating KIR genes,
KIR2DS1 and KIR2DS2, combined with the presence of
their specific ligands C2 and C1, respectively (KIR2DS1/
HLA-C2: 66.7 vs. 35.3 %, p = 0.03; KIR2DS2/HLA-C1:
63.3 vs. 20.6 %, p = 0.004). Higher frequencies were also
observed in this group of patients for the inhibitory KIR
genes, KIR2DL1 and KIR2DL2, combined with the pres-
ence of their specific ligands C2 and C1, respectively
(KIR2DL1/HLA-C2: 81.8 vs. 57.8 %, p = 0.021; KIR2DL2/
HLA-C1: 62.7 vs. 32.3 %, p = 0.018).Overall survival and progression-free survival following
treatment and according to KIR haplotype and iPET-2
In the cohort of 135 patients, 5-year OS and PFS was
93.6 and 79 %, respectively (Fig. 1). PFS was significantly
higher in patients who achieved negative iPET compared
to those who did not (89.8 vs. 55.8 %, p = 0.0001); among
patients with negative iPET, those homozygous for KIR
A haplotype had higher PFS rates compared to those
carrying Bx haplotypes, although the difference was not
statistically significant (92.3 vs. 85.3 %) (Fig. 2).
Discussion
Survival for advanced-stage cHL patients has increased to
70–85 % over the past years, but the optimal balance of
the risks and benefits of treatment is still a matter of de-
bate. At 15 years from the end of treatment, the risk of
dying from lymphoma is less than the risk of dying from
therapy-related complications [23]. The main dilemma re-
mains whether frontline intensive chemotherapy should
be given to all patients or be restricted to patients who are
poor responders to less intensive treatment approaches.
So far, iPET-2 scan represents the only strong predictor of
response to treatment [2]. There are currently no other
available prognostic biomarkers capable of distinguishing
Table 2 KIR and HLA gene frequencies, KIR haplotypes, and KIR-HLA ligand combinations in 135 advanced-stage classic HL patients
and 221 healthy controls
Patients (135) Percent Controls (221) Percent p OR (95 % CI)
Activating KIR
KIR2DS1 72 53.3 97 43.9.
KIR2DS2 78 57.8 125 56.6
KIR2DS3 54 40.0 77 34.9
KIR2DS4 124 91.9 202 91.4
KIR2DS5 42 31.1 75 33.9
KIR3DS1 53 39.3 88 39.8
Inhibitory KIR
KIR2DL1 132 97.8 215 97.2
KIR2DL2 80 59.2 126 57.0
KIR2DL3 123 91.1 188 85.0
KIR2DL4 135 100 221 100
KIR2DL5 78 57.8 116 52.5
KIR3DL1 135 100 206 93.2
KIR3DL2 135 100 219 99.1
KIR3DL3 135 100 221 100
KIR genotypes
AA 42 31.1 66 29.9
Bx 93 68.8 155 70.1
AA/C1-C1 2 4.8 35 15.7 0.001 0.08 (0.013–0.35)
KIR ligands
C1 pres 81 60.0 161 72.7 0.014 0.56 (0.35–0.90)
C2 pres 120 88.9 168 76 0.003 2.5 (1.31–4.90)
HLA-Bw4 pres 90 66.9 175 79.2
Activating KIR and their ligands
KIR2DS1 pres/HLA-C2 pres 56 41.5 78 35.3
KIR2DS1 pres/HLA-C2 abs 16 11.9 19 11.6
KIR2DS2 pres/HLA-C1 pres 46 34.1 80 36.2
KIR2DS2 pres/HLA-C1 abs 32 23.7 45 20.4
KIR3DS1 pres/HLA-Bw4 pres 32 23.7 74 33.5
KIR3DS1 pres/HLA-Bw4 abs 21 15.5 14 6.3 0.006 2.7 (1.27–5.9)
Inhibitory KIR and their ligands
KIR2DL1 pres/HLA-C2 pres 100 74.1 164 74.2
KIR2DL1 pres/HLA-C2 abs 32 23.7 51 23.1
KIR2DL2 pres/HLA-C1 pres 47 34.8 83 37.6
KIR2DL2 pres/HLA-C1 abs 32 23.7 43 19.5
KIR2DL3 pres/HLA-C1 pres 78 57.8 132 59.7
KIR2DL3 pres/HLA-C1 abs 45 33.3 56 25.3
KIR3DL1 pres/HLA-Bw4 pres 90 63.7 159 71.9
KIR3DL1 pres/HLA-Bw4 abs 45 33.3 47 21.3 0.013 1.9 (1.1–3.1)
abs absent, pres present, OR odds ratio, CI confidence interval, Ile isoleucine, Thr threonine
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Table 3 KIR and HLA gene frequencies, KIR haplotypes, and KIR-HLA ligand combinations in 135 advanced-stage classic Hodgkin
lymphoma patients according to positive or negative interim PET-2 results
PET-2 positive no. 33 % 24.4 PET-2 negative no. 102 % 75.6 p OR (95 % CI)
Activating KIR
KIR2DS1 23 69.7 49 48.0
KIR2DS2 27 81.8 51 50.0 0.001 4.5 (1.6–13.3)
KIR2DS3 16 48.5 38 37.3
KIR2DS4 28 84.9 96 94.1
KIR2DS5 9 27.3 33 32.3
KIR3DS1 16 48.5 37 36.3
Inhibitory KIR
KIR2DL1 33 100 99 97.1
KIR2DL2 22 66.7 58 56.9
KIR2DL3 30 90.9 93 91.2
KIR2DL4 33 100 102 100
KIR2DL5 20 60.6 58 56.9
KIR3DL1 33 100 102 100
KIR3DL2 33 100 102 100
KIR3DL3 33 100 102 100
KIR genotypes
AA 5 15.2 37 36.3 0.03 0.31 (0.1–0.95)
Bx 28 84.8 65 63.7
KIR ligands
C1 pres 22 66.7 74 72.5
C2 pres 27 81.8 88 86.3
HLA-Bw4 pres 24 72.7 66 64.7
Activating KIR and their ligands
KIR2DS1 pres/HLA-C2 pres 22 66.7 36 35.3 0.03 7.94 (0.496–173)
KIR2DS1 pres/HLA-C2 abs 1 3.3 13 12.7
KIR2DS2 pres/HLA-C1 pres 21 63.3 21 20.6 0.004 5.0 (1.55–16.8)
KIR2DS2 pres/HLA-C1 abs 6 18.2 30 29.4
KIR3DS1 pres/HLA-Bw4 pres 11 33.3 17 16.7
KIR3DS1 pres/HLA-Bw4 abs 5 15.6 20 19.6
Inhibitory KIR and their ligands
KIR2DL1 pres/HLA-C2 pres 27 81.8 59 57.8 0.021 3.05 (1.07–9.11)
KIR2DL1 pres/HLA-C2 abs 6 18.2 40 42.2
KIR2DL2 pres/HLA-C1 pres 19 62.7 33 32.3 0.018 4.8 (1.2–23.1)
KIR2DL2 pres/HLA-C1 abs 3 9.1 25 24.5
KIR2DL3 pres/HLA-C1 pres 23 69.7 55 53.9
KIR2DL3 pres/HLA-C1 abs 7 21.2 38 37.3
KIR3DL1 pres/HLA-Bw4 pres 22 66.7 65 63.7
KIR3DL1 pres/HLA-Bw4 abs 11 33.3 37 36.3
abs absent, pres present, OR odds ratio, CI confidence interval, Ile isoleucine, Thr threonine
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this reason, many ongoing studies focus their efforts on
the definition of new predictive factors for prognosis andresponse to treatment in cHL. Ideally, risk assessment
should combine innovative predictive biomarkers with
new imaging technologies [24–27].
Fig. 1 Overall survival (OS) and progression-free survival (PFS) in the
cohort of 135 patients. CI confidence interval
Fig. 2 Progression-free survival (PFS) in the cohort of 102 patients with neg
(p = NS). CI confidence interval
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model for the assessment of immunologic and immu-
nogenetic factors that may confer susceptibility to tu-
mors or facilitate tumor immune escape mechanisms
[4, 5]. Currently few data exist on the role of impaired
NK cell function in immune escape of HRS cells.
Besson et al. investigated association between KIRs
and cHL in a family study [18]. They provide evidence
that activating KIR genes, in particular KIR2DS1 and
KIR3DS1, may exert protection in cHL. In our cohort
of patients, we found a significantly higher frequency
for KIR3DS1 in the absence of its specific Bw4 ligand,
suggesting that this activating KIR gene cannot prop-
erly exert its protective function. No other significant
differences were observed between cHL patients and
controls for single KIR gene frequencies. Vice versa,
when we analyzed C1 and C2 epitopes, we found that
C2 had a significantly higher frequency in cHL pa-
tients (88.9 vs. 76 %, p = 0.008). Conversely, the C1
epitope was significantly higher in healthy controls
(72.7 vs. 60, p = 0.036) (Table 2). Interestingly, homo-
zygosity for KIR A haplotype and HLA-C1 ligand
(KIRAA/C1C1) was significantly higher in healthy
controls, suggesting a possible protective role in cHL
(15.7 vs. 4.8 %, p = 0.001) (Table 2).ative interim PET, stratified in two groups according to KIR haplotype
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homozygosity for HLA-C1 and KIR haplotype A could
be associated to a better immune response with resist-
ance to viral infection [10]. It is possible that the fixed
gene content of KIR A haplotypes with their highly poly-
morphic receptors provides better immune surveillance
against viral infections, whereas KIR B haplotypes with
their greater variation in gene content and moderate
allelic polymorphism could have an important role in
immune-tolerance during pregnancy [10]. Our data
seem to suggest a protective role for the KIRAA/C1C1
genotype in cHL.
In our study, KIR A haplotype was the only factor
significantly associated to a negative iPET-2 result sug-
gesting its favorable role in the achievement of better
response to standard chemotherapy. Moreover, the com-
bination of negative iPET-2 with homozygosity for KIR
A haplotype seems to represent a favorable combination
for identifying patients responsive to standard courses of
chemotherapy (PFS = 92.3 %) (Fig. 2).
Finally, we found that cHL patients with iPET-2 posi-
tivity had higher frequencies of the KIR-ligand combi-
nations KIR2DS1/HLA-C2 and KIR3DS2/HLA-C1. The
interaction between KIR2DS1, KIR2DS2, and their
HLA-C ligands might increase the production of tumor
growth factor (TGF)-β by NK cells. It has been sug-
gested that TGF-β may reduce tumor lysis mediated by
NK cells and stimulate the production of proinflamma-
tory cytokines such as tumor necrosis factor alpha
(TNF-α) and interferon gamma (IFN-γ) [28].Conclusions
Our results, though preliminary, seem to show that
homozygosity for KIR A haplotype, alone or in combin-
ation with homozygosity for the HLA-C1 KIR ligand,
confers protection to cHL. The association found for the
KIR-AA genotype and achievement of negative iPET-2
suggests that testing for KIR haplotypes could be used in
clinical practice to enhance the power of iPET-2 in pre-
dicting better treatment outcome in cHL patients. Over-
all, our findings may represent a rationale for developing
new risk-adapted treatment strategies based on the com-
bination of KIR biomarkers and PET scans. They fur-
thermore strengthen the hypothesis of innovative and
targeted therapies aimed at modulating NK cell function.
The use of anti-inhibitory-KIR antibodies could prove to
be an effective way of blocking the binding interface of
inhibitory KIRs with HLA class I ligands expressed by
lymphoma cells, thus preventing a tolerogenic inter-
action and augmenting NK cell cytotoxicity [28–31].Competing interests
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